WARRANT TO PURCHASE SHARES OF COMMON STOCKTearLab Corp • May 9th, 2016 • Surgical & medical instruments & apparatus • Delaware
THIS CERTIFIES THAT, for value received, [ ], or its registered assigns (the “Holder”), is entitled, subject to the provisions and upon the terms and conditions set forth herein, to purchase from Tearlab Corporation, a Delaware corporation (the “Company”), shares of the Company’s common stock, $0.001 par value per share (the “Shares”), in the amounts, at such times and at the price per share set forth in Section 1. The term “Warrant” as used herein shall include this Warrant and any warrants delivered in substitution or exchange therefor as provided herein. This Warrant is issued in connection with the transactions described in the Term Loan Agreement, dated as of March 4, 2015, by and between the Company, the Subsidiary Guarantors party thereto, and Capital Royalty Partners II L.P., Capital Royalty Partners II – Parallel Fund “A” L.P. and Parallel Investment Opportunities Partners II L.P., as amended.
CONFIDENTIAL TREATMENT REQUESTEDConfidential Treatment Requested • May 9th, 2016 • TearLab Corp • Surgical & medical instruments & apparatus • England
CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. INFORMATION THAT WAS OMITTED IN THE EDGAR VERSION HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[***]”.
AMENDMENT 4 TO TERM LOAN AGREEMENTTerm Loan Agreement • May 9th, 2016 • TearLab Corp • Surgical & medical instruments & apparatus • New York
THIS AMENDMENT 4, dated as of April 7, 2016 (this “Amendment”) is made among TearLab Corporation, a Delaware corporation (“Borrower”), the subsidiary guarantors listed on the signature pages hereof under the heading “SUBSIDIARY GUARANTORS” (each a “Subsidiary Guarantor” and, collectively, the “Subsidiary Guarantors”) and the lenders listed on the signature pages hereof under the heading “LENDERS” (each a “Lender” and, collectively, the “Lenders”), with respect to the Loan Agreement referred to below.
